Category:National_Institute_of_Allergy_and_Infectious_DiseasesNational_Institute_of_Allergy_and_Infectious_DiseasesNational_Institute_of_Allergy_and_Infectious_DiseasesNational_Institute_of_Allergy_and_Infectious_Diseases%D9%85%D8%A4%D8%B3%D8%B3%D9%87_%D9%85%D9%84%DB%8C_%D8%A2%D9%84%D8%B1%DA%98%DB%8C_%D9%88_%D8%A8%DB%8C%D9%85%D8%A7%D8%B1%DB%8C%E2%80%8C%D9%87%D8%A7%DB%8C_%D8%B9%D9%81%D9%88%D9%86%DB%8CNational_Institute_of_Allergy_and_Infectious_Diseases%D7%94%D7%9E%D7%9B%D7%95%D7%9F_%D7%94%D7%9C%D7%90%D7%95%D7%9E%D7%99_%D7%9C%D7%90%D7%9C%D7%A8%D7%92%D7%99%D7%94_%D7%95%D7%9E%D7%97%D7%9C%D7%95%D7%AA_%D7%9E%D7%99%D7%93%D7%91%D7%A7%D7%95%D7%AA_(%D7%90%D7%A8%D7%A6%D7%95%D7%AA_%D7%94%D7%91%D7%A8%D7%99%D7%AA)%E3%82%A2%E3%83%A1%E3%83%AA%E3%82%AB%E5%9B%BD%E7%AB%8B%E3%82%A2%E3%83%AC%E3%83%AB%E3%82%AE%E3%83%BC%E3%83%BB%E6%84%9F%E6%9F%93%E7%97%87%E7%A0%94%E7%A9%B6%E6%89%80%EB%AF%B8%EA%B5%AD_%EA%B5%AD%EB%A6%BD_%EC%95%8C%EB%A0%88%EB%A5%B4%EA%B8%B0%C2%B7%EC%A0%84%EC%97%BC%EB%B3%91_%EC%97%B0%EA%B5%AC%EC%86%8C%E0%B4%A8%E0%B4%BE%E0%B4%B7%E0%B4%A3%E0%B5%BD_%E0%B4%87%E0%B5%BB%E0%B4%B8%E0%B5%8D%E0%B4%B1%E0%B5%8D%E0%B4%B1%E0%B4%BF%E0%B4%B1%E0%B5%8D%E0%B4%B1%E0%B5%8D%E0%B4%AF%E0%B5%82%E0%B4%9F%E0%B5%8D%E0%B4%9F%E0%B5%8D_%E0%B4%93%E0%B4%AB%E0%B5%8D_%E0%B4%85%E0%B4%B2%E0%B5%BC%E0%B4%9C%E0%B4%BF_%E0%B4%86%E0%B5%BB%E0%B4%A1%E0%B5%8D_%E0%B4%87%E0%B5%BB%E0%B4%AB%E0%B5%86%E0%B4%95%E0%B5%8D%E0%B4%B7%E0%B5%8D%E0%B4%AF%E0%B4%B8%E0%B5%8D_%E0%B4%A1%E0%B4%BF%E0%B4%B8%E0%B5%80%E0%B4%B8%E0%B5%8DNational_Institute_of_Allergy_and_Infectious_DiseasesInstituto_Nacional_de_Alergia_e_Doen%C3%A7as_Infecciosas%D0%9A%D0%B0%D1%82%D0%B5%D0%B3%D0%BE%D1%80%D0%B8%D1%8F:%D0%9D%D0%B0%D1%86%D0%B8%D0%BE%D0%BD%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B9_%D0%B8%D0%BD%D1%81%D1%82%D0%B8%D1%82%D1%83%D1%82_%D0%B0%D0%BB%D0%BB%D0%B5%D1%80%D0%B3%D0%B8%D0%B8_%D0%B8_%D0%B8%D0%BD%D1%84%D0%B5%D0%BA%D1%86%D0%B8%D0%BE%D0%BD%D0%BD%D1%8B%D1%85_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D0%B9%E0%AE%A4%E0%AF%87%E0%AE%9A%E0%AE%BF%E0%AE%AF_%E0%AE%92%E0%AE%B5%E0%AF%8D%E0%AE%B5%E0%AE%BE%E0%AE%AE%E0%AF%88_%E0%AE%AE%E0%AE%B1%E0%AF%8D%E0%AE%B1%E0%AF%81%E0%AE%AE%E0%AF%8D_%E0%AE%A4%E0%AF%8A%E0%AE%B1%E0%AF%8D%E0%AE%B1%E0%AF%81%E0%AE%A8%E0%AF%8B%E0%AE%AF%E0%AF%8D%E0%AE%95%E0%AE%B3%E0%AF%8D_%E0%AE%95%E0%AE%B4%E0%AE%95%E0%AE%AE%E0%AF%8DQ3519875%E7%BE%8E%E5%9C%8B%E5%9C%8B%E5%AE%B6%E9%81%8E%E6%95%8F%E5%92%8C%E5%82%B3%E6%9F%93%E7%97%85%E7%A0%94%E7%A9%B6%E6%89%80
about
Ethan M. ShevachJulie LedgerwoodStephen StrausRick M. FairhurstChanaki AmaratungaYasmine BelkaidSriram NarayananJ. Michael BishopDavid O. FreedmanMauricio L. NogueiraBernard A. LafontMichael A. PolisMichael William VogelPeter A ZimmermanSeyedmojtaba SeyedmousaviPietro MiozzoVictor V LobanenkovOliver LaeyendeckerTiago R FerreiraSheldon M. WolffJeff SkinnerHarry MalechArunakumar GangaplaraEric CalvoTomohiko SadaokaUn-in WuFabio M GomesMargery G SmelkinsonRebecca S PelcFrank R. DeLeoMichael P. FayClifton E BarryJan C. PreißR Burke SquiresRita CzakoTejram SahuLindsey S GarverJosé M. RibeiroKirsten SpannAdriana Marques
P108
3BNC117-LS and 10-1074-LS in Viremic HIV-infected IndividualsDecreasing Antibiotic Prescribing in Acute Respiratory Infections Through Nurse Driven Clinical Decision SupportA Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy VolunteersVNRX-7145 SAD/MAD Safety and PK in Healthy Adult VolunteersProspective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD PatientsThe Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following VaccinationPre-SunBeam TEWL AUCDevelopment of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral DrugsAdapting Motivational Interviewing for Maternal Immunizations (MI4MI)Effectiveness of a Pre-adolescent Inter-generational Intervention to Address HIV and ObesityRTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in MalawiVNRX-5024 Safety and PK in Healthy Adult VolunteersSafety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048UNCPMZ 41901 - MP3 PrEP StudyImpact of Indoor Residual Spraying on Aedes-borne DiseasesSimplifying Treatment and Monitoring for HIVUnderstanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19International SARS-CoV-2 (COVID-19) Infection Observational StudyRandomized Cross-Over Study of Self-Insertion of Two Placebo Vaginal Film FormulationsCharacterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
P767
Characterization of Lethal Zika Virus Infection in AG129 MiceRandomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease VaccineIdentification of three noncontiguous regions on Bacillus anthracis plasmid pXO1 that are important for its maintenanceHfqs in Bacillus anthracis: Role of protein sequence variation in the structure and function of proteins in the Hfq familyIn vivo characterization of an Hfq protein encoded by the Bacillus anthracis virulence plasmid pXO1Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway.The diphthamide modification on elongation factor-2 renders mammalian cells resistant to ricin.Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.ImmPortEffect of over expressing protective antigen on global gene transcription in Bacillus anthracis BH500Use of Busulfan as Conditioning Agent for a Second Stem Cell TransplantHigh Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseHaploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant CyclophosphamideAnalysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsZIKA Vaccine in Naive SubjectsPhase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic AreaA Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy AdultsVRC 705: A Zika Virus DNA Vaccine in Healthy Adults and AdolescentsInvestigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in ChildrenLethal Factor Domain-Mediated Delivery of Nurr1 Transcription Factor Enhances Tyrosine Hydroxylase Activity and Protects from Neurotoxin-Induced Degeneration of Dopaminergic CellsApheresis to Obtain Plasma or White Blood Cells for Laboratory StudiesGenetic Analysis of Immune DisordersStudy of Mast Cell PrecursorsMagnetic Resonance Imaging of the Face and BonesImmune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral TherapyComparison of Immune Response in Normal Volunteers and Patients With Helminth InfectionsAntibody Production in Immune DisordersEffect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With SchistosomiasisNexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in TuberculosisLongitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United StatesA Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy SubjectsStudy of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive AdultsStudy of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy AdultsStudy of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African AdultsDAS181 in Patients With ParainfluenzaCollection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal VolunteersA Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic DermatitisMeasurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
P859
Q30427362-ddbae781-49a6-e6c5-714e-9c3e3379cd90Q30791301-7f2bf645-4719-0b61-f780-1349775c8c4bQ33206594-E16BFB1F-D1A5-43E4-A707-D0F542315BE2Q33357446-15e5b781-44a7-d6ca-207e-f5a27317cbb2Q34056663-3D7A477A-A61E-4C62-897B-06B3DF9AD9A8Q34056663-AA7FA171-80B4-450F-8FBE-BBFE1B6E846AQ34056663-C4D76CCC-57FA-4695-86C4-A9CBF8256343Q36211969-904EC041-102C-4C58-928F-8C171D905B09Q36211969-F6E57E5B-16D2-4726-BD38-F1105F6723B6Q36306550-00FB8398-F076-428F-86EF-7C55522CE5BFQ36306550-7854B77F-20DF-4F20-8C75-B0CD61FB8CF4Q36306550-9934AC3F-FA9A-423E-8F63-B1DD22232D4EQ36306550-F68FB827-F9A8-46A2-80A9-D786F5928BBFQ36926511-A7CDC1DC-2F32-4A65-90F1-F9DF07EE5A0CQ37375271-634E4CA2-3A84-4A78-953A-6F56D6BC5DFEQ38949958-3cb8eae1-46e9-e8e3-f282-c6c4da132cf0Q39588214-2BB763A6-E620-4ABE-A31E-64C8B35D8975Q39588214-A0F63294-8D3D-4C09-8772-DFBEEBE4369AQ40746895-d8949d5d-46eb-3446-3976-067e2e4dee66Q44756776-f5802336-4c5c-bf37-c378-13a1b35b2875Q44796798-bd890111-46aa-07f7-a289-a6ddf179a075Q48864003-dd15a074-49d8-2c32-4815-9363a1bd00a1Q57459044-B6DE5EC6-8611-4425-B853-9BC27CE80D21Q57459044-E8C740EA-9E40-415A-81C0-C7861C28FB93Q58091960-2a22659a-4305-2988-df12-156b171f5c60Q59127270-47a80040-440b-436c-0803-e7cc60eb719cQ59127270-78908530-4f1d-01ac-0e57-3512d68de5a2Q59127270-8e2a8fa7-4cb0-4a0c-7786-3dd8379d2381Q61154258-AD0FB06B-951A-46DE-BB22-3A1FA72A061EQ61647171-367bbebc-4d32-0de4-dc3a-c44e12ef8b85Q62018048-630209E6-6C4D-412B-9D1A-177628D61F36Q62018048-68489D1A-D17A-481C-BF42-888AC665384AQ62018048-981E5977-7693-4E27-8526-CA4A034E6FADQ62018048-C4450F39-45CE-44E8-A723-73EB5219FC41Q62580112-98f27642-4ba7-6d7f-ce74-85281c357923Q62730421-33EFD4EC-24A4-47BB-B933-008BA32EB504Q62772972-E8D0D20C-F6C3-4F57-9164-98C592D660E7Q62772972-F23CDA92-1992-4909-9B04-6FF9889D6CA6Q64827088-F8C87491-002B-4BD5-AB81-07130E9CFBC0Q82412742-86B366BB-6221-417C-92A9-D28F3FF63E70
P1416
description
US research institute for the treatment and prevention of infectious diseases
@en
סוכנות של מחלקת הבריאות ושירות ...... עיקרית האחראית למחקר ביו-רפואי
@he
name
Instituto Nacional de Alergia e Doenças Infecciosas
@pt
NIAID
@ko
National Institute of Allergy and Infectious Diseases
@de
National Institute of Allergy and Infectious Diseases
@en
National Institute of Allergy and Infectious Diseases
@es
National Institute of Allergy and Infectious Diseases
@fr
National Institute of Allergy and Infectious Diseases
@nb
National Institute of Allergy and Infectious Diseases
@nl
National Institute of Allergy and Infectious Diseases
@sv
Viện Nghiên cứu Dị ứng và Bệnh Truyền nhiễm Quốc gia
@vi
type
label
Instituto Nacional de Alergia e Doenças Infecciosas
@pt
NIAID
@ko
National Institute of Allergy and Infectious Diseases
@de
National Institute of Allergy and Infectious Diseases
@en
National Institute of Allergy and Infectious Diseases
@es
National Institute of Allergy and Infectious Diseases
@fr
National Institute of Allergy and Infectious Diseases
@nb
National Institute of Allergy and Infectious Diseases
@nl
National Institute of Allergy and Infectious Diseases
@sv
Viện Nghiên cứu Dị ứng và Bệnh Truyền nhiễm Quốc gia
@vi
altLabel
NIAID
@en
NIAID
@es
NIAID
@pt
NIAID
@vi
National Institute of Allergy and Infectious Diseases
@pt
مؤسسه ملی آلرژی و بیماری های واگیردار ایالات متحده
@fa
مؤسسه ملی الرژی و بیماری های واگیردار ایالات متحده امریکا
@fa
مؤسسهٔ ملی آلرژی و بیماری های واگیردار ایالات متحدهٔ آمریکا
@fa
موسسه ملی آلرژی و بیماری های واگیردار ایالات متحده آمریکا
@fa
موسسه ملی آلرژی و بیماری های واگیردار ایالات متحده
@fa
prefLabel
Instituto Nacional de Alergia e Doenças Infecciosas
@pt
NIAID
@ko
National Institute of Allergy and Infectious Diseases
@de
National Institute of Allergy and Infectious Diseases
@en
National Institute of Allergy and Infectious Diseases
@es
National Institute of Allergy and Infectious Diseases
@fr
National Institute of Allergy and Infectious Diseases
@nb
National Institute of Allergy and Infectious Diseases
@nl
National Institute of Allergy and Infectious Diseases
@sv
Viện Nghiên cứu Dị ứng và Bệnh Truyền nhiễm Quốc gia
@vi